# M.D. Anderson Cancer Center: Phase 2 study closed enrollment, 15 enrolled (SMARCB1-Deficient Malignancies, Epithelioid Sarcoma)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | M.D. Anderson Cancer Center |
| Sponsor type | Academic and hospital |
| Study | Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies |
| NCT ID | NCT06444880 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | SMARCB1-Deficient Malignancies; Epithelioid Sarcoma; Renal Medullary Carcinoma |
| Intervention types | drug |
| Target enrollment | 15 |
| Site countries | United States |
| Posted | 2024-06-06 |
| Planned start | 2024-10-09 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-11-03 |
| Last update posted | 2026-11-03 |

## Why this score
- Posted in the last two weeks.
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06444880). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.